Fourth-gen CAR T Cells Targeting BCMA/CD19 therapy(Essen Biotech)

N/A

Report date: 2024/05/27 17:06:46

Base Information

Drug NameFourth-gen CAR T Cells Targeting BCMA/CD19 therapy(Essen Biotech)
Drug Alias NameSequential CAR-T Cells Targeting BCMA/CD19 therapy(Essen Biotech)BCMA/CD19 CAR-T cells therapy(Essen Biotech)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsB-lymphocyte antigen CD19 modulatorsB-cell maturation protein modulators
TargetsB-lymphocyte antigen CD19B-cell maturation protein
Therapy Area/IndicationsAutoimmune DiseasesScleroderma, SystemicLupus Erythematosus, Systemic +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesEssen Biotech
China Registration ClassN/A

Develop Information

Active CompaniesEssen Biotech
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesScleroderma, SystemicLupus Erythematosus, Systemic +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A